The doctoral thesis was defended in the Department of Pharmacology, College of Medicine, University of Al-Nahrain, presented by the student Nawar Raad Hussein, titled: "The Anti-Angiogenesis Effect of Phenyl Azoserine Derivatives C26H22N4O4 and C28H23N5O4: In Vivo and In Vitro Assays in Rats" The aim of the thesis was to: Identify anti-metastatic agents and the anti-angiogenesis activity of the phenyl azoserine derivatives C28H23N5O4 and C26H22N4O4 both in vitro, in vivo, in laboratory settings, and in silico, as well as to verify the gene expression of Vascular Endothelial Growth Factor (VEGF) in Kaposi Sarcoma cells. The study reached several important findings, the most prominent of which are: Both derivatives exhibited the ability to inhibit angiogenesis using the mouse aortic ring assay and the chicken chorioallantoic membrane (CAM) assay. Both derivatives also demonstrated anti-proliferative properties when tested on human umbilical vein endothelial cells (HUVECs) and cancer cells from the colon and breast. Both derivatives led to a significant reduction in VEGF, as measured by quantitative reverse transcription polymerase chain reaction (qRT-PCR) at a concentration of 200 µg/mL. The results were further supported by computational analysis, which indicated several targets, including protein G receptors, integrins, caspase 1, neprilysin, and angiotensin-converting enzyme. Molecular docking of the phenyl azoserine derivatives (C28H23N5O4 and C26H22N4O4) showed a precise linear potential (PLP) of 91.496 and 81.783, respectively, and they had low binding energy for hypoxia-inducible factor 1 alpha (HIF-1α), angiopoietin-1, and fibroblast growth factor (FGF). On the other hand, the study showed that phenyl azoserine derivatives effectively inhibit angiogenesis in various experimental models, as evidenced by the significant suppression of VEGF gene expression through reverse transcription polymerase chain reaction, indicating their potential as anti-cancer agents pending clinical approval. 
|
